Marshall Wace’s Repare Therapeutics RPTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-1,115,744
Closed -$2.9M 3618
2025
Q4
$2.9M Buy
+1,115,744
New +$2.25M ﹤0.01% 1403
2025
Q1
Sell
-46,876
Closed -$61.4K 3027
2024
Q4
$61.4K Sell
46,876
-72,232
-61% -$215K ﹤0.01% 2478
2024
Q3
$410K Buy
119,108
+36,518
+44% +$120K ﹤0.01% 1994
2024
Q2
$273K Buy
+82,590
New +$295K ﹤0.01% 2191
2024
Q1
Sell
-26,866
Closed -$196K 2757
2023
Q4
$196K Buy
+26,866
New +$150K ﹤0.01% 1983
2023
Q1
Sell
-39,489
Closed -$581K 3049
2022
Q4
$581K Buy
+39,489
New +$591K ﹤0.01% 2316
2022
Q3
Sell
-30,900
Closed -$433K 3732
2022
Q2
$433K Buy
+30,900
New +$364K ﹤0.01% 2862

Marshall Wace's RPTX Position: Q1 2026 in Review

Marshall Wace sold out of Repare Therapeutics (RPTX) in Q1 2026, closing a stake of 1,115,744 shares — an estimated $2.9M sold.

Marshall Wace first reported a position in RPTX in Q2 2022 and held it in 7 quarters. The position peaked at $2.9M in Q4 2025. 0 funds tracked by Wall St. Rank hold RPTX as of Q1 2026.

  • Marshall Wace reported no remaining Repare Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Marshall Wace sold 1,115,744 Repare Therapeutics shares in Q1 2026, an estimated $2.9M.
  • Marshall Wace first reported a position in Repare Therapeutics in Q2 2022 and held it in 7 quarters.
  • Marshall Wace's Repare Therapeutics position peaked at $2.9M in Q4 2025.
  • 0 funds tracked by Wall St. Rank held Repare Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.